Sachs on TwitterFollow us on Twitter @SachsAssociates
sachs associates   ANNUAL
Sachs Immuno-Oncology:
BD&L and Investment Forum
    29th May 2015 • Hyatt Chicago Magnificent Mile • USA
Delegates, Presenting
& Emerging Companies,
Organisations, Academia
sachs sachs sachs sachs sachs sachs sachs
Biotech i Europe Investor Forum
sachs sachs



The Sachs Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 200 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be two tracks of about 30 presentations by listed and private biotechnology companies seeking licensing/investment.


The Sachs Immuno-Oncology: BD&L and Investment Forum
will feature panels on:

  • Pharma-Biotech BD&L
  • Immunotherapeutics: ADCs and Combination Therapies
  • T Cell Therapeutics
  • Academic Medical Center Collaborations
  • Investment Roundtable

Confirmed Chairs & Speakers include: (for speakers bios click here)

    "Cancer Drug Pricing"

    – David H. Howard, Associate Professor, Department of Health Policy and Management,
    Emory University
    "Pitfalls and promise of genetically modified T-Cells"
    – Peter Emtage, Ph.D., Vice President, Immunology Research, Intrexon Corporation

    BLOOMBERG NEWS Interview by Cynthia Koons with:
    Arie Belldegrun, Chairman, President and CEO, Kite Pharma

    Ali Fattaey, Chief Executive Officer, Curis, Inc.
    André Choulika, Chairman and CEO, Cellectis
    Behzad Aghazadeh, Managing Partner, venBio LLC
    Biren Amin, Managing Director and Senior Equity Research Analyst, Jefferies, LLC
    Boris Peaker, Managing Director, Cowen and Company
    Charles Nicolette, Chief Scientific Officer & V.P. R&D, Argos Therapeutics
    David Donabedian, Vice President & Head, Ventures and Early Stage Collaborations,
    AbbVie, Inc.
    Elma Hawkins, President and CEO, Lion Biotechnologies
    Eva Jack, CBO, Mersana Therapeutics
    Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center
    Gregory Frost, SVP, Head of Health Sector, Intrexon Corporation
    Guillaume Vignon, Director Business Development Oncology, Global Licensing & Business Development, Merck Serono SA
    Hamza Suria, President & Chief Executive Officer, AnaptysBio, Inc.
    Henry H. Ji, Director, President & CEO, Sorrento Therapeutics, Inc.
    Howard J. Fingert, Senior Medical Director, Internal and External Innovation for Oncology TA, Takeda Pharmaceuticals
    Ioannis Sapountzis, Global Head, Oncology Business Development and Licensing,
    Boehringer Ingelheim GmbH
    Issi Rozen, Senior Director, Strategic Alliances, Broad Institute of MIT and Harvard
    James Mulé, Associate Center Director for Translational Research, Michael McGillicuddy Endowed Chair of Melanoma Research and Treatment, and Director of Cell-based Therapies, Moffitt Cancer Center
    Jarett Rieger, Director, OTMC & Associate General Counsel, Moffitt Cancer Center
    Jason Coloma, Vice President, Head of Oncology and Cancer Immunology Partnering, Roche
    Jeffrey Bacha, President & CEO, Del Mar Pharmaceuticals
    Ji Li, Vice President, Business Development and Licensing, Merck Research Laboratories
    John DeYoung, Vice President, Worldwide Business Development, Pfizer, Inc.
    Jonathan Pachter, VP, Head of Research, Verastem, Inc.
    Joseph Sum, Director of Research, EcoR1 Capital, LLC
    Kevin Slawin, Founder, Chief Technology Officer, Bellicum Pharmaceuticals, Inc.
    Kuldeep Neote, Senior Director, New Venture and Scout, J&J Innovation Center-Boston
    Lee Greenberger, Chief Scientific Officer, The Leukemia and Lymphoma Society
    Margarita Chavez, Director, Ventures & Early Stage Collaborations, AbbVie, Inc.
    Maxim Jacobs, Senior Healthcare Analyst, Edison Group
    Mike Attar, Executive Director, Business Development, Celgene
    Mike Rice, Senior Consultant, Defined Health
    O. Prem Das, Chief Business Development Officer, Dana-Farber Cancer Institute
    Peter Hoang, Senior Vice President, Business Development & Strategy,
    Bellicum Pharmaceuticals, Inc.
    Peter Sandor, Vice President, Global Marketing Oncology, Amgen
    Peter Thompson, Private Equity Partner, OrbiMed Advisors, LLC
    Reginald Seeto, Vice President, Head of Partnering & Strategy, Medimmune
    Richard Gregory, EVP & Chief Scientific Officer, ImmunoGen, Inc.
    Robert Petit, Chief Scientific Officer, Executive Vice President, Advaxis, Inc.
    Sharon Benzeno, Senior Director, New Product Development, Adaptive Biotechnologies
    Stephen Rubino, Global Head, Business Development and New Products Marketing, Cell & Gene Therapy Unit, Novartis Pharmaceuticals Corporation
    Tanja Weber, Strategy & Business Development, VP Oncology Corporate Licenses, Sanofi
    Thilo Schroeder, Partner, Nextech Invest Ltd
    * to be confirmed

Presenting Opportunities for Biotech, Pharmaceutical companies and Patient Advocacy Groups

Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed minute presentations.

Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Chicago forum provides the additional interaction with the academic/scientific and patient advocacy communities.

Sponsorship and Exhibition

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please contact
Silvia Kar on + 44 (0)203 463 4890 or by email: Silvia.


Sponsored and Supported by:

Sponsors & Supporters
Click the cover below to view/download the online forum guide.
Sachs - Immuno-Oncology: BD&L and Investement Forum

Login in NOW – add your profile directly to the system and start booking your meetings.

To learn more about presenting, exhibition or sponsorship opportunities, please contact Silvia Kar
+ 44 (0)203 463 4890 or by email:
Silvia Kar.
  Meeting Scheduler
1-2-1 Meeting system